| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
We established a subclone of ID8 mouse ovarian cancer cell line (ID8-T6) which more quickly forms peritoneal dissemination. IL-33 was up-regulated in both ID8-T6 cells and tissue compared with for ID8. We confirmed the expression of IL-33 in human epithelial ovarian cancer (EOC) cell lines. Unexpectedly, the survival rate of IL33-overexpressing subclone (ID8-IL33) tumor-bearing mice was significantly prolonged compared with that of ID8-mock tumor-bearing mice. Infiltrating CD4+ cells and CD8+ cells within the disseminated tumor tissues were significantly increased in ID8-IL33 tumors compared with in ID8-mock tumors. In contrast, myeloid-derived suppressor cells (MDSCs) were significantly decreased in IL33-overexpressing tumors. Ascites from ID8-IL33 tumor-bearing mice inhibited MDSC differentiation. EOC patients with high staining of IL-33 had significantly longer overall survival times.
We also established ID8 chemo-resistant subclones and heterogeneity assessment mouse models.
|
